291,666 Shares in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Purchased by Samsara BioCapital LLC

Samsara BioCapital LLC acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 291,666 shares of the company's stock, valued at approximately $4,506,000. Artiva Biotherapeutics makes up about 0.9% of Samsara BioCapital LLC's investment portfolio, making the stock its 23rd largest position. Samsara BioCapital LLC owned approximately 1.20% of Artiva Biotherapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. BNP Paribas Financial Markets bought a new stake in Artiva Biotherapeutics in the third quarter valued at about $42,000. MetLife Investment Management LLC acquired a new position in shares of Artiva Biotherapeutics during the third quarter worth about $135,000. Charles Schwab Investment Management Inc. acquired a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $623,000. Acuta Capital Partners LLC acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $680,000. Finally, RTW Investments LP bought a new position in Artiva Biotherapeutics during the third quarter worth about $2,300,000.

Analyst Upgrades and Downgrades

ARTV has been the subject of a number of analyst reports. Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a "buy" rating and a $21.00 price target for the company. Cantor Fitzgerald assumed coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued an "overweight" rating and a $23.00 target price on the stock. TD Cowen initiated coverage on shares of Artiva Biotherapeutics in a report on Tuesday, August 13th. They set a "buy" rating on the stock. Needham & Company LLC reissued a "buy" rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Finally, Wedbush restated an "outperform" rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Friday, August 30th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $21.25.

Artiva Biotherapeutics Stock Performance

Shares of ARTV traded down $0.23 during trading hours on Thursday, reaching $12.49. 54,823 shares of the stock traded hands, compared to its average volume of 125,499. Artiva Biotherapeutics, Inc. has a 52-week low of $9.68 and a 52-week high of $17.31. The company's 50-day simple moving average is $12.56.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.24). On average, equities research analysts predict that Artiva Biotherapeutics, Inc. will post -4.68 earnings per share for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.